LOG IN
SIGN UP
MARKET
AKBA
AKBA
Akebia Therapeut
NASDAQ
Real-time Quotes | Nasdaq Last Sale
0.4061
+0.0171
+4.40%
Opening 14:11 07/05 EDT
OPEN
0.3882
PREV CLOSE
0.3890
HIGH
0.4250
LOW
0.3775
VOLUME
13.46M
TURNOVER
3.75M
52 WEEK HIGH
3.709
52 WEEK LOW
0.3000
MARKET CAP
74.53M
P/E (TTM)
-0.2523
1D
5D
1M
3M
1Y
5Y
Why Is Akebia Therapeutics (AKBA) Stock Up 14% Today?
Investor Place · 4d ago
Wall Street Set for Losses as Recession Fears Linger
MT Newswires · 4d ago
BRIEF-Akebia Therapeutics Regaining Rights To Vadadustat In The United States, Europe, China And Access Consortium Countries Upon Termination Of Collaboration And License Agreements With Otsuka
BRIEF-Akebia Therapeutics Regaining Rights To Vadadustat In The United States, Europe, China And Access Consortium Countries Upon Termination Of Collaboration And License Agreements With Otsuka
Reuters · 4d ago
Akebia regains rights to kidney disease therapy after termination of deals with Otsuka
Akebia Therapeutics (NASDAQ:AKBA) on Thursday <a href="...
Seekingalpha · 4d ago
Akebia Therapeutics Regaining Rights to Vadadustat in the United States, Europe, China and Access Consortium Countries upon Termination of Collaboration and License Agreements with Otsuka
Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that it has executed an agreement to terminate the U.S. and ex-U.S. vadadustat Collaboration a...
PR Newswire · 4d ago
Akebia to Get $55 Million Settlement Fee After Ending Vadadustat Deal with Otsuka; Stock Up 35% After-Hours
MT Newswires · 5d ago
Akebia Therapeutics (AKBA) Stock Soars 18% Despite Lack of News
Investor Place · 6d ago
18 Stocks Moving in Thursday's Pre-Market Session
Gainers View, Inc. (NASDAQ: VIEW) rose 18.5% to $2.05 in pre-market trading after declining 5% on Wednesday.
Benzinga · 06/09 10:13
No Data
Learn about the latest financial forecast of AKBA. Analyze the recent business situations of Akebia Therapeut through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating
Based on 5 analysts
Hold
Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.
0.00%Strong Buy
0.00%Buy
80.00%Hold
20.00%Under-perform
0.00%Sell
Analyst Price Target
The average AKBA stock price target is 1.417 with a high estimate of 2.000 and a low estimate of 1.000.
Current 0.4071
EPS
Actual
Estimate
-0.41-0.31-0.20-0.10
Institutional Holdings
Institutions: 228
Institutional Holdings: 85.58M
% Owned: 46.63%
Shares Outstanding: 183.53M
TypeInstitutionsShares
Increased
39
4.47M
New
18
1.02M
Decreased
43
6.92M
Sold Out
25
14.02M
- Performance
- Asset Allocation
- Dividend History
No Data
Industry
Biotechnology & Medical Research
+1.47%
Pharmaceuticals & Medical Research
-0.48%
Key Executives
Non-Executive Chairman/Independent Director
Adrian Adams
President/Chief Executive Officer/Director
John Butler
Chief Financial Officer/Senior Vice President/Treasurer
David Spellman
Chief Operating Officer/Senior Vice President
Michel Dahan
Senior Vice President/Secretary
Nicole Hadas
Senior Vice President
Steven Burke
Senior Vice President
Dell Faulkingham
Independent Director
Ronald Frieson
Independent Director
Steven Gilman
Independent Director
Michael Rogers
Independent Director
Cynthia Smith
Independent Director
Myles Wolf
Independent Director
Leanne Zumwalt
No Data
No Data
About AKBA
Akebia Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on producing medicines for people living with kidney disease. Its lead product candidate, vadadustat, is an oral therapy in development for the treatment of anemia due to chronic kidney disease (CKD). Vadadustat is an oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI), designed to mimic the physiologic effect of altitude on oxygen availability. In addition, it has a commercial product, Auryxia (ferric citrate), which is marketed for two indications in the United States: the control of serum phosphorus levels in adult patients with dialysis-dependent (DD)-CKD or the hyperphosphatemia indication, and the treatment of iron deficiency anemia (IDA), in adult patients with non-dialysis dependent (NDD)-CKD or the IDA indication. Its ferric citrate is also approved and marketed in Japan as an oral treatment for the improvement of hyperphosphatemia in patients with CKD.
Webull offers kinds of Akebia Therapeutics Inc stock information, including NASDAQ:AKBA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, AKBA stock news, and many more online research tools to help you make informed decisions.
You can practice and explore trading AKBA stock methods without spending real money on the virtual paper trading platform.